Recent News

• 04.03.2024 - ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
• 03.19.2024 - ObsEva Announces Update on Board of Directors
• 02.28.2024 - ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
• 01.31.2024 - Geneva Court Grants Temporary Moratorium to ObsEva
• 11.30.2023 - ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
• 10.27.2023 - Organon Returns Ebopiprant to XOMA
• 09.27.2023 - ObsEva Files half Year 2023 Financial Statements
• 07.13.2023 - ObsEva Recovers Full Worldwide Rights on Nolasiban
• 06.30.2023 - ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023 Annual General Meeting held on June 29, 2023
• 06.08.2023 - Annual General Meeting 2023

Recent Filings